MedTrace Logo

Microwave Ablation Simultaneously Combined With Lenavatinib for Recurrent Hepatocellular Carcinoma

NCT05444478 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 274

Last updated 2023-11-07

No results posted yet for this study

Summary

This study intends to evaluate the efficacy and safety of microwave ablation combined lenvatinib simultaneously for recurrent HCC

Conditions

Interventions

PROCEDURE

Microwave ablation

only microwave ablation for tumor

DRUG

Lenvatinib

lenvatinib (80 mg for body no more than 60kg，120 mg for body weight \>60 kg)

Sponsors & Collaborators

  • Sun Yat-sen University

    lead OTHER

Principal Investigators

  • Xianhai Mao, Professor · Hunan Provincial People's Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-07-01
Primary Completion
2025-07-01
Completion
2027-07-01

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05444478 on ClinicalTrials.gov